We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells

By LabMedica International staff writers
Posted on 17 Jan 2024
Print article
Image: Principle and construction of the palm-size optofluidic hematology analyzer (Photo courtesy of OES)
Image: Principle and construction of the palm-size optofluidic hematology analyzer (Photo courtesy of OES)

Variations in blood cell concentration can be indicative of several health conditions, including infections, inflammatory diseases, malignant blood disorders, and AIDS (Acquired Immune Deficiency Syndrome). Detecting these variations is crucial for diagnosing, treating, and managing these diseases. Traditional methods for measuring blood cell concentration, like using a hemocytometer, typically require an optical microscope. Alternatively, flow cytometers offer a more efficient method for sorting and counting blood cells in fluids, but they are often large and complex, weighing between 9-30 kg, thus limiting their use to laboratory and hospital settings. This restricts the availability of point-of-care testing (POCT) and can delay treatment for patients. Now, a proposed portable smart blood cell analyzer could help overcome the limitations of conventional methods for blood cell concentration detection.

Developed by the Harbin Institute of Technology (HIT, Heilongjiang, China), this innovative analyzer integrates a miniature fluorescence microscope, typically used in neuroscience and behavioral research, with a microfluidic platform. This design significantly reduces the analyzer's size and weight, resulting in a device that measures 35 × 30 × 80 mm and weighs only 39 g, making it substantially lighter than conventional flow cytometers. The analyzer combines image processing with leukocyte counting algorithms to enhance leukocyte information and accurately determine their concentration.

The effectiveness of the proposed analyzer was validated by comparing its leukocyte concentration measurements with those of a standard hemocytometer using Passing-Bablok analysis, achieving a correlation coefficient of 0.979. A Bland-Altman analysis further confirmed the analyzer’s reliability, establishing a 95% limit of agreement ranging from -0.93×10³ to 0.94×10³ cells/μL. The analyzer's error rate in calculating leukocyte concentration was found to be less than 10%, meeting the accuracy standards set by both the UK National External Quality Assessment Service (NEQAS) and the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88). The development of this palm-size optofluidic hematology analyzer is expected to facilitate the POCT of blood cells outside traditional hospital or laboratory settings, thus enhancing medical diagnosis in remote or underserved areas.

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.